Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of JTX-4014 (Pimivalimab) in Advanced Solid Tumors
NCT03790488Phase 1Completed
- Sponsor
- Jounce Therapeutics
- Start
- Dec 2018
- Primary completion
- Jul 2019
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of pimivalimab in solid tumor (advanced stage), sponsored by Jounce Therapeutics. Primary endpoints: Percentage of subjects with adverse events (AEs) at 12 months, Percentage of subjects with serious adverse events (SAEs) at 12 months and 4 more. Started Dec 2018; status: completed.
02
Drugs
pimivalimab
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT03790488.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03790488.